One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus - PubMed (original) (raw)

. 2015 Oct;160(2):155-62.

doi: 10.1016/j.clim.2015.06.003. Epub 2015 Jun 11.

Affiliations

One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus

Edwin J P van Asseldonk et al. Clin Immunol. 2015 Oct.

Abstract

Inflammation associated with obesity is involved in the development of insulin resistance. We hypothesized that anti-inflammatory treatment with the Interleukin-1 receptor antagonist anakinra would improve insulin sensitivity. In an open label proof-of-concept study, we included overweight patients diagnosed with type 1 diabetes with an HbA1c level over 7.5%. Selecting insulin resistant patients with longstanding type 1 diabetes allowed us to study the effects of anakinra on insulin sensitivity. Patients were treated with 100mg anakinra daily for one week. Insulin sensitivity, insulin need and blood glucose profiles were measured before, after one week and after four weeks of follow-up. Fourteen patients completed the study. One week of anakinra treatment led to an improvement of insulin sensitivity, an effect that was sustained for four weeks. Similarly, glucose profiles, HbA1c levels and insulin needs improved. In conclusion, one week of treatment with anakinra improves insulin sensitivity in patients with type 1 diabetes.

Keywords: Adipose tissue; Anakinra; Inflammation; Insulin sensitivity; Interleukin 1; Type 1 diabetes.

Copyright © 2015 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources